<DOC>
	<DOCNO>NCT01766128</DOCNO>
	<brief_summary>The aim study investigation neuroprotective effect zonisamide early Parkinson disease . A total 60 patient early Parkinson disease meet study criterion enrol randomize two group alternately base visit date . Demographic data , Unified Parkinson 's Disease Rating Scale ( UPDRS ) , modify Hoehn &amp; Yahr modify Schwab &amp; England activity daily live scale determine registered patient . Patients group A treat zonisamide 50mg/d 12 month group treat placebo time . Primary endpoint occurrence parkinsonian symptom interfere patient ' daily activity cause psychosocial embarrassment . The mentioned score register every 2 month group blind neurologist also regular blood test perform prevent drug adverse event .</brief_summary>
	<brief_title>Study Zonisamide Early Parkinson Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>1 . Age 4585 year 2 . Symptoms sign idiopathic Parkinson disease less month lead physical psychosocial disability . 1 . Past history treatment antiparkinson drug . 2 . Past history treatment zonisamide 3 . Hepatic insufficiency ( ALT &gt; 2ULN ) 4 . Renal insufficiency ( Cr &gt; 2mg/dl ) 5 . Self family history nephrolithiasis 6 . Active psychosis 7 . Epilepsy 8 . Suicidal attempt last 3 year 9 . Hypersensitivity sulfonamides 10 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Parkinson disease</keyword>
	<keyword>Early stage</keyword>
	<keyword>Zonisamide</keyword>
	<keyword>UPDRS</keyword>
</DOC>